Bioinspired natural delivery vehicles have the potential to address critical, unmet needs in the treatment of cancer and other severe human diseases. We are a team of scientists dedicated to developing cell-derived vehicles for precision delivery and novel strategies for treating human cancer. Combining existing cancer therapies with individualized human tumor organoid models and the cutting-edge precision delivery technologies for RNA therapeutics and oncolytic viruses, we will develop next-generation combinational immunotherapy strategies with a focus on malignant lung cancer. We welcome diverse interdisciplinary collaborations.
Yunjun received her master’s degree of Science from Sun Yat-Sen University, Zhongshan School of Medicine. She joined the Wang lab in Feb 2022 as a research assistant and lab manager. She is an experienced researcher in immunology and virology and is enthusiastic about managing and organizing the lab.
Xin graduated from an 8-year program of undergraduate and postgraduate courses in clinical medicine and received her master’s degree of medicine at Chongqing Medical University. She was a clinician at Department of Pulmonary and Critical Care Medicine, Xinqiao Hospital. She will start the biomedical engineering graduate program in the fall of 2022, which is a joint program from School of Life Science, Fudan University and Greater Bay Area Institute of Precision Medicine (Guangzhou). She is passionate about contributing to the lab's goal of creating new bioinspired therapeutics to treat cancer.
Dan received her M.Sc. degree in the College of Agriculture & Life Science from the Department of Biochemistry and Molecular Biology at Mississippi State University in May of 2016, working on molecular characterization of extracellular vesicles released from mammalian circadian clock cells. She pursued her Ph.D. degree in Poultry Science at Texas A&M University, where she characterized the roles of microRNAs in broiler chick-Salmonella interactions and established a model system of chicken intestinal organoids for studying host-pathogen interaction and fundamental research. She joined the GBA-IPM as a postdoctoral scholar in June 2022 and focused on using state-of-the-art organoid technologies to develop novel immunotherapies against human cancer.
Postdoc positions are open for motivated junior scientists who are enthusiastic about precision delivery and immunotherapy. Previous rigorous training and extensive knowledge about cell biology, cancer biology, immunology, preclinical animal models, cell engineering, and cell therapy are preferred but not required. Candidates with multidisciplinary backgrounds are encouraged to apply. Upon completion of training, a postdoc certificate will be granted by Fudan University, China.
